Summary
Amarantus Bioscience Holdings Inc (Amarantus), formerly Amarantus BioSciences, Inc., discovers and develops treatments for various therapeutic diseases. The company’s therapeutics pipeline products include eltoprazine and mesencephalic-astrocyte-derived neurotrophic factor. Its diagnostics include lymphocyte proliferation test, nuropro blood test and DNA sequencing assay. Amarantus provides DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. The company also offers phenoguard protein discovery engine platform. It provides products for cell cycle dysfunction, endoplasmic reticulum stress, astrocyte-neuron biology, neurodegeneration and apoptosis. The company develops diagnostics and therapeutics pipeline products for diseases associated with neurodegeneration and apoptosis. Amarantus is headquartered in San Francisco, California, the US.
Amarantus Bioscience Holdings Inc (AMBS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2011 to YTD 2017 10
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Amarantus BioScience to Acquire Certain Biotechnology Assets from SeD BioMedical 13
Venture Financing 14
Amarantus Therapeutics Raises US$1.3 Million In Venture Financing 14
Partnerships 14
Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 14
Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 15
Licensing Agreements 16
Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 16
Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 17
Amarantus Bioscience to Enter into Licensing Agreement with University of Leipzig 18
Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 19
Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 20
Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 21
Equity Offering 22
Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 22
Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 23
Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 24
Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 25
Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 26
Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 27
Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Amarantus BioSciences Enters Into Equity Funding Facility With Centurion Private Equity For US$10 Million 29
Debt Offering 30
Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 30
Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For US$1.6 Million 31
Acquisition 33
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 33
Jumpkicks Acquires Amarantus Therapeutics 34
Amarantus Bioscience Holdings Inc - Key Competitors 35
Key Employees 36
Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38
List of Tables
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Amarantus Bioscience Holdings Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2011 to YTD 2017 10
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Amarantus BioScience to Acquire Certain Biotechnology Assets from SeD BioMedical 13
Amarantus Therapeutics Raises US$1.3 Million In Venture Financing 14
Amarantus BioScience Enters into Cooperative Research and Development Agreement with USAISR and Rutgers University 14
Amarantus Bioscience Enters into Research Agreement with Buck Institute for AMRS-001 15
Amarantus BioScience Enters into Option for Licensing Agreement with Georgetown University 16
Amarantus Bioscience Exercises Option for Licensing Agreement with Bascom Palmer Eye Institute 17
Amarantus Bioscience to Enter into Licensing Agreement with University of Leipzig 18
Amarantus Bioscience Enters Into Option For Licensing Agreement With University of Massachusetts 19
Amarantus Enters Into Licensing Agreement With PGI Drug Discovery For Eltoprazine 20
Amarantus Bioscience Enters Into Licensing Agreement With University of Massachusetts Medical School 21
Amarantus BioScience Raises USD3.3 Million in Private Placement of Shares 22
Amarantus BioScience Raises USD1 Million in Private Placement of Series H Preferred Stock 23
Amarantus Bioscience Raises USD2.75 Million in Private Placement of Series H Preferred Stock and Warrants 24
Amarantus Bioscience Raises USD5 Million in Private Placement of Series G Preferred Stock 25
Amarantus Bioscience to Raise Additional USD1 Million in Series E Preferred StockFinancing Round 26
Amarantus Bioscience Raises USD2 Million in Second Tranche of Private Placement 27
Amarantus Bioscience Raises USD0.4 Million in First Tranche of Private Placement of Shares 28
Amarantus BioSciences Enters Into Equity Funding Facility With Centurion Private Equity For US$10 Million 29
Amarantus BioScience to Raise USD1.5 Million in Private Placement of 10% Notes Due 2017 and Warrants 30
Amarantus Bioscience Announces Second Tranche Of Private Placement Of Debentures For US$1.6 Million 31
Amarantus BioScience Acquires Cutanogen from Lonza Walkersville for USD9.3 Million 33
Jumpkicks Acquires Amarantus Therapeutics 34
Amarantus Bioscience Holdings Inc, Key Competitors 35
Amarantus Bioscience Holdings Inc, Key Employees 36
Amarantus Bioscience Holdings Inc, Other Locations 37
Amarantus Bioscience Holdings Inc, Subsidiaries 37
List of Figures
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Amarantus Bioscience Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Amarantus Bioscience Holdings Inc, Medical Devices Deals, 2011 to YTD 2017 10
